Conceptus Essure
This article was originally published in The Gray Sheet
Executive Summary
Non-incisional permanent birth control manufacturer releases pivotal trial data from 518-patient, multicenter trial May 7 at the American College of Obstetricians and Gynecologists annual meeting. Of 507 women, or 98% of the study subjects who attempted placement, 92% achieved bilateral placement. The 98% who completed bilateral placement and completed three-month follow-up were able to rely on the device for contraception. In addition, 92% of employed women were able to return to work the next day. The firm submitted its PMA application on April 19 and anticipates going before FDA panel as early as July (1"The Gray Sheet" March 25, 2002, p. 21)...
You may also be interested in...
Conceptus Essure Contraceptive Could Go To Panel As Early As July
Conceptus believes that FDA's Obstetrics and Gynecology Devices Panel could review the company's Essure non-incisional permanent birth control procedure PMA as early as July or October
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.